FDA Approves Austedo!!

Samuel Frank, MD,is an associate professor of Neurology at Beth Israel Deaconess Medical Center and Harvard Medical School. After completing his residency and fellowship at the University of Rochester, he joined the neurology faculty at Boston University from 2004 to 2015. Dr. Frank is an active member of the Huntington Study Group, having served as a principal investigator and as a member of HSG’s executive committee. He has also served as a member of HDSA’s Board of Trustees and is the director of the HDSA Center of Excellence at Beth Israel Deaconess Medical Center. Dr. Frank is the inpatient neurology consultant for the specialized Huntington’s Disease service at Tewksbury Hospital. Dr. Frank was the principal investigator for First-HD, a Phase 3 clinical trial investigating deuterated tetrabenazine as a possible treatment for chorea associated with HD. Last week, the FDA approved the new drug based on positive results from the First-HD trial, which was led by the Huntington Study Group (HSG) on behalf of Teva Pharmaceuticals.